Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
View/ Open
Date
2017-01Author
Collins, DC
Sundar, R
Lim, JSJ
Yap, TA
Type
Journal Article
Metadata
Show full item recordAbstract
Precision medicine continues to be the benchmark to which we strive in cancer research. Seeking out actionable aberrations that can be selectively targeted by drug compounds promises to optimize treatment efficacy and minimize toxicity. Utilizing these different targeted agents in combination or in sequence may further delay resistance to treatments and prolong antitumor responses. Remarkable progress in the field of immunotherapy adds another layer of complexity to the management of cancer patients. Corresponding advances in companion biomarker development, novel methods of serial tumor assessments, and innovative trial designs act synergistically to further precision medicine. Ongoing hurdles such as clonal evolution, intra- and intertumor heterogeneity, and varied mechanisms of drug resistance continue to be challenges to overcome. Large-scale data-sharing and collaborative networks using next-generation sequencing (NGS) platforms promise to take us further into the cancer 'ome' than ever before, with the goal of achieving successful precision medicine.
Collections
Subject
Humans
Neoplasms
Biopsy
Immunotherapy
Drug Resistance, Neoplasm
Clinical Trials as Topic
High-Throughput Nucleotide Sequencing
Biomarkers, Tumor
Precision Medicine
Research team
Medicine Drug Development Unit (de Bono)
Language
eng
Date accepted
2016-10-19
License start date
2017-01
Citation
Trends in pharmacological sciences, 2017, 38 (1), pp. 25 - 40